Source: Diagnos
  • Diagnos (ADK) receive approval from the Costa Rican regulatory agency for its Artificial Intelligence (AI) enabled Pathology Detection Systems
  • This allows commercial deployment of the systems in Costa Rica
  • Ocular diseases is the leading cause of blindness in the world
  • Diagnos (ADK) is a Canadian corporation dedicated to early detection of critical health problems based on its FLAIRE platform based on AI
  • Diagnos (ADK) unchanged today, trading at C$0.19 as of Aug 18, 2022, 1:44 pm ET

Diagnos (ADK) has received approval from the Costa Rican regulatory agency for its Artificial Intelligence (AI) enabled Pathology Detection Systems.

The company’s platform complies with legal requirements and regulations. The approval is valid for five years and allows commercial deployment of the Pathology Detection Systems in Costa Rica. The registration will be held for Diagnos by Costa Rican-based Aselcom, a local partner specializing in selling medical technologies to hospitals, medical clinics, and optical stores.

The VP of Sales, Guillermo Moreno says:

“This approval represents US$1,500,000 of potential revenues for our company.”

Ocular diseases are now the leading cause of blindness worldwide in patients between the ages of 20 and 64. In Costa Rica, 15 per cent of its population over 20 have diabetes. However, only 11 per cent of these cases are diagnosed. Of the diagnosed patients, 35 per cent were identified with diabetic retinopathy, a disease known to affect vision severely.

The President of Diagnos, Andre Larente says:

“We are very grateful to both the Quebec and Canadian Government for working with us closely on this approval for our Pathology Detection Systems in Costa Rica. This announcement reflects Diagnos’ commitment to continue to deploy our innovative Pathology Detection technology using Ocular Images not just in select countries, but worldwide.”

Diagnos (ADK) is a Canadian corporation dedicated to early detection of critical health problems based on its FLAIRE platform based on AI.

Diagnos (ADK) unchanged today, trading at C$0.19 as of Aug 18, 2022, 1:44 pm ET.


More From The Market Online

Calian scores $23 million Canadian Armed Forces contract

Calian Group Ltd. (TSX:CGY) has been awarded a $17 million contract by the Canadian Armed Forces’ Canadian Forces Health Services Group.

Unsung profits: Three microcap stocks with a strong case for value

A key factor behind picking winning microcap value stocks is identifying dislocations between company performance and market perception.

This life sciences company is gearing up to treat long COVID  

Revive Therapeutics (CSE:RVV), a Toronto-based company, has immense potential to capitalize on treating long COVID symptoms.

Theralase advances cancer research after private placement

Theralase Technologies (TSXV:TLT) closes a non-brokered private placement offering of 4.1 million shares for gross proceeds of C$750,200.